罗格列酮用于多囊卵巢综合征患者促排卵周期的疗效观察

Efficacy of Rosiglitazone in promoting ovulation of the PCOS

目的 探讨罗格列酮对多囊卵巢综合征有胰岛素抵抗 (IR)患者促排卵治疗的效果。方法 将 2 0 0 1年 6月至 2 0 0 2年 6月 81例患者随机分为A、B、C三组 ,分别给予促排卵药、罗格列酮、罗格列酮与促排卵药合用 ,比较三组用药前后胰岛素抵抗指数 (HomaIR)、游离脂肪酸 (FFA)、肿瘤坏死因子 (TNFα)和排卵率的变化。结果 罗格列酮治疗前后患者HomaIR指数、血清FFA和TNFα明显下降 (P <0 0 5 )。C组排卵率明显优于A组 (P <0 0 5 )和B组 (P <0 0 0 5 )。结论 罗格列酮能有效地改善胰岛素抵抗 ,提高排卵率。

Objective To investigate the ovulation promoting effects of Rosiglitazone(Avandia) in the treatment of PCOS with insulin-resistance(IR).Methods 81 cases of IR from June 2001 to June 2002 were divided randomly into three groups:group A received Gn only,group B received Rosiglitazone only,and group C received both Gn and Rosiglitazone.In three groups,Homa IR,the ovulation rate,FFA and TNFα before the treatment were compared with those after treatment,and the same indicators as above after the treatment were compared with each other.Results In the patients who received Rosiglitazone treatment,serum levels of FFA,TNFα and Homa IR decreased significantly after treatment ( P<0 05) .The ovulation rate of group C were remarkably higher than group A and B(P<0 05,P<0 005),respectively.Conclusion Rosiglitazone can effectively ameliorate the condition of IR and promote ovulation.